Cited by 115Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma

Calles, Antonio, Sholl, Lynette M., Rodig, Scott J., Pelton, Ashley K., Hornick, Jason L., Butaney, Mohit, Lydon, Christine, Dahlberg, Suzanne E., Oxnard, Geoffrey R., Jackman, David M., Jänne, Pasi A.·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-3112

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non–small cell lung cancer (NSCLC). Experimental Design: We optimized and validated an IHC assay for LKB1 (clone Ley37D/G6) using a panel of lung cancer cell lines and tumors with known LKB1 mutations, including 2 patients with Peutz–Jeghers syndrome (PJS) who developed lung adenocarcinoma. We retrospectively analyzed tumors for LKB1 using IHC from 154 KRAS-mutant NSCLC patients, including 123 smokers and 31 never-smokers, and correlated the findings with patient and tumor characteristics and clinical outcome. Results: LKB1 expression was lost by IHC in 30% of KRAS-mutant NSCLC (smokers 35% vs. never-smokers 13%, P = 0.017). LKB1 loss did not correlate with a specific KRAS mutation but was more frequent in tumors with KRAS transversion mutations (P = 0.029). KRAS-mutant NSCLC patients with concurrent LKB1 loss had a higher number of metastatic sites at the time of diagnosis (median 2.5 vs. 2, P = 0.01), higher incidence of extrathoracic metastases (P = 0.01), and developed brain metastasis more frequently (48% vs. 25%, P = 0.02). There was a nonsignificant trend to worse survival in stage IV KRAS-mutant NSCLC patients with LKB1 loss. Conclusions: LKB1 IHC is a reliable and efficient assay to evaluate for loss of LKB1 in clinical samples of NSCLC. LKB1 loss is more common in smokers, and is associated with a more aggressive clinical phenotype in KRAS-mutant NSCLC patients, accordingly to preclinical models. Clin Cancer Res; 21(12); 2851–60. ©2015 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-3112

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I. P. M., Avizienyte, E., Roth, S., Loukola, A., Bignell, G. R., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,680
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase
Jenne, D. E., Reomann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Müller, O., Back, W. E., & Zimmer, M. (1998) · Nature Genetics · doi:10.1038/ng0198-38 · Cited by 1,201
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655

Show all 50 references

Sorted by citations

Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Rekhtman, N., Pietanza, M. C., Hellmann, M. D., Naidoo, J., Arora, A., Won, H. H., Halpenny, D. F., Wang, H., Tian, S. K., Litvak, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2946 · Cited by 488
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Lou, Y., Diao, L., Parra, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 452
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., et al. (2017) · Nature · doi:10.1038/nature22359 · Cited by 325
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Calles, A., Liao, X., Sholl, L. M., Rodig, S. J., Freeman, G. J., Butaney, M., Lydon, C., Dahlberg, S. E., Hodi, F. S., Oxnard, G. R., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000687 · Cited by 273
Self-citation
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Chen, P.-H., Cai, L., Huffman, K. E., Yang, C., Kim, J., Faubert, B., Boroughs, L. K., Ko, B., Sudderth, J., McMillan, E. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.028 · Cited by 209
MCT4-Dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-Deficient NSCLC
Qian, Y., Galán‐Cobo, A., Guijarro, I., Dang, M., Molkentine, D. P., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 206
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Chen, Z., Li, J., Lin, S., Cao, C., Gimbrone, N. T., Yang, R., Fu, D., Carper, M. B., Haura, E. B., Schabath, M. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85250 · Cited by 192
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Arrieta, O., Barrón, F., Padilla, M.-Á. S., Avilés-Salas, A., Ramírez-Tirado, L. A., Arguelles Jiménez, M. J., Vergara, E., Zatarain-Barrón, Z. L., Hernández-Pedro, N., Cardona, A. F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2553 · Cited by 179
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Seguin, L., Durandy, M., & Féral, C. C. (2022) · Cancers · doi:10.3390/cancers14071759 · Cited by 188
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 164
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Kim, J., Lee, H. M., Cai, F., Ko, B., Yang, C., Lieu, E. L., Muhammad, N., Rhyne, S., Li, K., Haloul, M., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00316-0 · Cited by 143
The mTOR–S6K pathway links growth signalling to DNA damage response by targeting RNF168
Xie, X., Hu, H., Tong, X., Li, L., Liu, X., Chen, M., Yuan, H., Xie, X., Li, Q., Zhang, Y., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0033-8 · Cited by 132
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 135
STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition
Sitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X. H., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 115
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Facchinetti, F., Bluthgen, M. V., Tergemina-Clain, G., Faivre, L., Pignon, J., Planchard, D., Remón, J., Soria, J., Lacroix, L., & Besse, B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.002 · Cited by 109
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC
Moro, M., Caiola, E., Ganzinelli, M., Zulato, E., Rulli, E., Marabese, M., Centonze, G., Busico, A., Pastorino, U., de Braud, F., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.102 · Cited by 103
Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Sholl, L. M. (2021) · Modern Pathology · doi:10.1038/s41379-021-00932-5 · Cited by 108
Self-citation
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S. L., Fontes, C., Shi, Y., Chalasani, P., & Janne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
Self-citation
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Bai, X., Guo, Z.-Q., Zhang, Y.-P., Fan, Z., Liu, L., Liu, L., Long, L.-L., Ma, S.-C., Wang, J., Fang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36892-4 · Cited by 72
Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer
Zhang, D., Ning, J., Okon, I. S., Zheng, X., Satyanarayana, G., Song, P., Xu, S., & Zou, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03793-7 · Cited by 65
Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1
Nagaraj, A. S., Lahtela, J., Hemmes, A., Pellinen, T. S., Blom, S., Devlin, J. R., Salmenkivi, K., Kallioniemi, O., Mäyränpää, M. I., Närhi, K. M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.059 · Cited by 63
LKB1 inactivation modulates chromatin accessibility to drive metastatic progression
Pierce, S. E., Granja, J. M., Corces, M. R., Brady, J. J., Tsai, M. K., Pierce, A. B., Tang, R., Chu, P., Feldser, D. M., Chang, H. Y., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00728-4 · Cited by 59
LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma
Liu, M., Gu, L., Zhang, Y., Li, Y., Zhang, L., Xin, Y., Wang, Y., & Xu, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217025 · Cited by 62
Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system
Gailite, I., Aerne, B. L., & Tapon, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505512112 · Cited by 58
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 55
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
Bonanno, L., De Paoli, A., Zulato, E., Esposito, G., Calabrese, F., Favaretto, A., Santo, A., Conte, A. D., Chilosi, M., Oniga, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2410 · Cited by 53
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications
Krishnamurthy, N., Goodman, A. M., Barkauskas, D. A., & Kurzrock, R. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.050 · Cited by 51
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
Garrido, P., Olmedo, M. E., Gómez, A., Ares, L. P., López‐Ríos, F., Rosa-Rosa, J. M., & Palacios, J. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719829 · Cited by 45
The Tumor Suppressor Kinase LKB1: Metabolic Nexus
Bourouh, M., & Marignani, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.881297 · Cited by 48
LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiation
Zulato, E., Ciccarese, F., Agnusdei, V., Pinazza, M., Nardo, G., Iorio, E., Curtarello, M., Silic‐Benussi, M., Rossi, E. M. C., Venturoli, C., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.019 · Cited by 42
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
Caiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 41
Inactivation of AMPK leads to attenuation of antigen presentation and immune evasion in lung adenocarcinoma
Gao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
Loss of FGL1 induces epithelial‑mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma
Bie, F., Wang, G., Qu, X. H., Wang, Y., Huang, C., Wang, Y., & Du, J. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4838 · Cited by 39
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
Lindsay, C. R., Shaw, E. C., Moore, D. A., Rassl, D. M., Jamal‐Hanjani, M., Steele, N. L., Naheed, S., Dick, C., Taylor, F., Adderley, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01407-9 · Cited by 38
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies
Fang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 37
The Molecular Pathology of Lung Cancer
Sholl, L. M. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.003 · Cited by 36
Self-citation
Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer
Shen, X., Zhao, Y., Liu, G., Zhou, H.-L., Fan, J., Zhang, L., Li, Y., Wang, Y., Liang, J., & Xu, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117923 · Cited by 33
2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells
Sun, L., Liu, X., Fu, H., Zhou, W., & Zhong, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168793 · Cited by 30
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
Hofman, V., Lassalle, S., Bence, C., Long-Mira, É., Nahon‐Estève, S., Heeke, S., Lespinet‐Fabre, V., Butori, C., Ilié, M., & Hofman, P. M. (2018) · Cancers · doi:10.3390/cancers10030070 · Cited by 28
A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma
Chen, L., Engel, B. E., Welsh, E. A., Yoder, S., Brantley, S. G., Chen, D., Beg, A. A., Cao, C., Kaye, F. J., Haura, E. B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.009 · Cited by 28
LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors
Trelford, C. B., & Shepherd, T. G. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01689-5 · Cited by 28
LKB1: Can We Target an Hidden Target? Focus on NSCLC
Ndembe, G., Intini, I., Perin, E., Marabese, M., Caiola, E., Mendogni, P., Rosso, L., Broggini, M., & Colombo, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889826 · Cited by 26
Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras‐driven lung tumours
Närhi, K. M., Nagaraj, A. S., Parri, E., Turkki, R., van Duijn, P. W., Hemmes, A., Lahtela, J., Uotinen, V., Mäyränpää, M. I., Salmenkivi, K., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5059 · Cited by 23
The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis
Xiao, J., Zou, Y., Chen, X., Gao, Y., Xie, M., Lu, X., Li, W., He, B., He, S., You, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152674 · Cited by 25
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress–Based Treatments
Borzi, C., Ganzinelli, M., Caiola, E., Colombo, M., Centonze, G., Boeri, M., Signorelli, D., Caleca, L., Rulli, E., Busico, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.005 · Cited by 24
Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
Gregorc, V., Lazzari, C., Mandalà, M., Ippati, S., Bulotta, A., Cangi, M. G., Khater, A., Viganò, M. G., Mirabile, A., Pecciarini, L., et al. (2021) · Cancers · doi:10.3390/cancers13092023 · Cited by 25
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
Cai, R., Zhu, H., Liu, Y. L., Sha, H., Peng, W., Yin, R. L., Zhou, G., & Fang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04919-4 · Cited by 28
Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas
Presneau, N., Duhamel, L. A., Ye, H., Tirabosco, R., Flanagan, A. M., & Eskandarpour, M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.174 · Cited by 23
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy
Mazzaschi, G., Leonetti, A., Minari, R., Gnetti, L., Quaini, F., Tiseo, M., & Facchinetti, F. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00891-8 · Cited by 21
The RSL3 Induction of KLK Lung Adenocarcinoma Cell Ferroptosis by Inhibition of USP11 Activity and the NRF2-GSH Axis
Zhang, W., Li, X., Xu, J., Wang, Y., Xing, Z., Hu, S., Fan, Q., Lu, S., Cheng, J., Gu, J., et al. (2022) · Cancers · doi:10.3390/cancers14215233 · Cited by 21
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Self-citation
Salvianolic acid B acts against non‑small cell lung cancer A549 cells via inactivation of the MAPK and Smad2/3 signaling pathways
Han, G., Wang, Y., Liu, T., Gao, J., Duan, F., Chen, M., Yang, Y., & Wu, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12700 · Cited by 22
Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies
Bourreau, C., Treps, L., Faure, S., Fradin, D., & Clere, N. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108347 · Cited by 20
Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
Davis, A. P., Cooper, W. A., Boyer, M. J., Lee, J., Pavlakis, N., & Kao, S. (2021) · Immunotherapy · doi:10.2217/imt-2021-0090 · Cited by 20
LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence
Mitchell, K. G., Parra, E. R., Zhang, J., Nelson, D. B., Corsini, E. M., Villalobos, P. A., Moran, C. A., Skoulidis, F., Wistuba, I. I., Fujimoto, J., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.03.114 · Cited by 16
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers
Donnelly, L. L., Hogan, T. C., Lenahan, S. M., Nandagopal, G., Eaton, J. G., Lebeau, M. A., McCann, C., Sarausky, H. M., Hampel, K. J., Armstrong, J. D., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab104 · Cited by 18
Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations
Ravichandran, R., Bansal, S., Rahman, M. A., Sureshbabu, A., Sankpal, N. V., Fleming, T. P., Bharat, A., & Mohanakumar, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861583 · Cited by 17
LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner
Bian, T., Wang, Y., Botello, J. F., Hu, Q., Jiang, Y., Zingone, A., Ding, H., Wu, Y., Aly, F. Z., Salloum, R. G., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02410-x · Cited by 16
The AMPK-HOXB9-KRAS axis regulates lung adenocarcinoma growth in response to cellular energy alterations
Wang, T., Guo, H., Li, Q., Wu, W., Yu, M., Zhang, L., Li, C., Song, J., Wang, Z., Zhang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111210 · Cited by 15
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review)
Han, P., Zhou, J., Xiang, J., Liu, Q., & Sun, K. (2022) · Oncology Reports · doi:10.3892/or.2022.8440 · Cited by 16
High-dose ascorbic acid selectively induces pyroptosis in LKB1-deficient lung cancer and sensitizes immunotherapy
Sun, X., Cai, X.-T., Li, S., Pi, R., Guo, Z.-Q., Jiang, J., Wang, P., Xiong, J., Liu, Z., Rong, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102291 · Cited by 14
Claudin-18 and Mutation Surrogate Immunohistochemistry in Gastric-type Endocervical Lesions and their Differential Diagnoses
Lin, L. H., Kaur, H. B., Kolin, D. L., Nucci, M. R., & Parra‐Herran, C. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002342 · Cited by 13
LKB1 expression and the prognosis of lung cancer
Lin, C., Lin, X., Lin, K., Tan, J., Wei, C., & Liu, T. (2021) · Medicine · doi:10.1097/md.0000000000027841 · Cited by 13
Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
Sfakianaki, M., Papadaki, C., Tzardi, M. N., Trypaki, M., Alam, S., Lagoudaki, E. D., Messaritakis, I., Zoras, O., Mavroudis, D., Georgoulias, V., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.008 · Cited by 13
Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
Tanaka, I., Koyama, J., Itoigawa, H., Hayai, S., & Morise, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249237 · Cited by 13
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
Borzi, C., Galli, G., Ganzinelli, M., Signorelli, D., Vernieri, C., Garassino, M. C., Sozzi, G., & Moro, M. (2020) · Pharmaceuticals · doi:10.3390/ph13110385 · Cited by 12
LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.
Zhang, K., Wang, J., Wang, J., Luh, F., Liu, X., Yang, L., Liu, Y., Su, L., Yang, Y. S. H., Chu, P. G., et al. (2019) · PubMed Central · Cited by 12
Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion
Xu, J., Guo, H., Xing, Z., Zhang, W., He, J., Cheng, J., & Cai, R. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6240125 · Cited by 12
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Aredo, J. V., & Padda, S. K. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0557-6 · Cited by 12
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
Self-citation
STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours
Dehghani, A., Sharma, A. E., Siegmund, S., Carreon, C. K., Stewart, C. J. R., Medeiros, F., Mirković, J., Nucci, M. R., Crum, C. P., Hornick, J. L., et al. (2024) · Histopathology · doi:10.1111/his.15303 · Cited by 10
Self-citation
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer
Shu, C., Li, J., Rui, J., Fan, D., Niu, Q., Bai, R., Cicka, D., Doyle, S. P., Wahafu, A., Zheng, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57297-5 · Cited by 11
Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis
Ren, Y., Zhao, F., Mo, H., Jia, R. R., Tang, J., Zhao, X. H., Wei, J. L., Huo, R. R., Li, Q. Q., & You, X. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027185 · Cited by 10
Aging and lung diseases: Unraveling mechanisms and therapeutic targets
Zhou, Y., Chen, G., Li, X., Li, X., Lin, Z., Liu, L., Pu, D., Chen, J., Chen, Y., Lin, Z., et al. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.11.005 · Cited by 10
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras -Mutant Lung Cancers
Talwelkar, S. S., Nagaraj, A. S., Devlin, J. R., Hemmes, A., Potdar, S., Kiss, E. A., Saharinen, P., Salmenkivi, K., Mäyränpää, M. I., Wennerberg, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0573 · Cited by 7
LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer
Lagoudaki, E. D., Koutsopoulos, A. V., Sfakianaki, M., Papadaki, C., Manikis, G. C., Voutsina, A., Trypaki, M., Tsakalaki, E., Fiolitaki, G., Hatzidaki, D., et al. (2024) · Cancers · doi:10.3390/cancers16101818 · Cited by 8
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
Vernieri, C., Ganzinelli, M., Rulli, E., Farina, G., Bettini, A., Bareggi, C., Rosso, L., Signorelli, D., Galli, G., Russo, G. L., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000748 · Cited by 8
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
Ricciuti, B., Brambilla, M., Cortellini, A., Giglio, A. D., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02175-y · Cited by 8
Genomic landscape and actionable mutations of brain metastases derived from non–small cell lung cancer: A systematic review
Andrews, L., Thornton, Z. A., Saleh, R., Dawson, S., Short, S. C., Daly, R. G., Higgins, J. P. T., Davies, P. A., & Kurian, K. M. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad145 · Cited by 8
Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients
Boldrini, L., Giordano, M., Lucchi, M., Melfi, F. M. A., & Fontanini, G. (2018) · Biomedical Reports · doi:10.3892/br.2018.1122 · Cited by 7
A subset of VEGFR‐TKIs activates AMPK in LKB1 ‐mutant lung cancer
Yang, L., Zhang, Q., Xiong, Y., Dang, Z., Xiao, H., Chen, Q., Dai, X., Zhang, L., Zhu, J., Wang, D., et al. (2022) · Cancer Science · doi:10.1111/cas.15677 · Cited by 5
Downregulation of a tumor suppressor gene LKB1 in lung transplantation as a biomarker for chronic murine lung allograft rejection
Rahman, M. A., Ravichandran, R., Sankpal, N. V., Bansal, S., Sureshbabu, A., Fleming, T. P., Perincheri, S., Bharat, A., Smith, M. A., Bremner, R. M., et al. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104690 · Cited by 6
Dual Checkpoint Inhibition: An Approach for STK11 and KRAS Co-Mutated Lung Adenocarcinoma?
Stein, M. K., Prouet, P., & Martin, M. G. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00211 · Cited by 6
Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1 , or KRAS : the TRITON study
Skoulidis, F., Borghaei, H., Garon, E. B., Leal, T. A. B., Kaufman, J., Liu, S. V., Nadler, E., Patel, S. P., Peters, S., Ricciuti, B., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251386611 · Cited by 5
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 6
A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives
Workman, S., Jabbour, S. K., & Deek, M. P. (2023) · AME Medical Journal · doi:10.21037/amj-2022-01 · Cited by 6
Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and interferon signaling in lung cancers harboring KEAP1/STK11 mutations
Lin, Z., Ashish, S., Huang, L., Li, S., Li, Y., Zhou, Y., & Gu, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1676797 · Cited by 6
Reduced levels of liver kinase B1 in small extracellular vesicles as a predictor for chronic lung allograft dysfunction in cystic fibrosis lung transplant recipients
Ravichandran, R., Rahman, M. A., Bansal, S., Scozzi, D., Fleming, T. P., Ratti, G. A., Arjuna, A., WEIGT, S. S., Kaza, V., Smith, M., et al. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111187 · Cited by 4
Therapeutic Outcomes and Clinical Features of Advanced Non–Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study
Mazzaschi, G., Perrone, F., Minari, R., Verzè, M., Azzoni, C., Bottarelli, L., Pluchino, M., Armillotta, M. P., Ubaldi, A., Altimari, A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.005 · Cited by 4
LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
Avilés‐Salas, A., Díaz-García, D. A., Lara‐Mejía, L., Cardona, A. F., Orozco‐Morales, M., Catalán, R., Hernández‐Pedro, N., Rios-Garcia, E., Ramos-Ramírez, M., & Arrieta, O. G. (2022) · Current Oncology · doi:10.3390/curroncol30010027 · Cited by 4
Co-mutations in tumor immune microenvironment and immunotherapy
Ma, L., Zhu, L., Xu, Z., & Shu, Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001455 · Cited by 4
Liver kinase B1 correlates with prognosis and epithelial-mesenchymal transition of resectable early stage non-small cell lung cancer
Qin, Z. S., Xie, R., Zhang, W., Wan, M., Zhang, L., Wang, H., Li, N., Qin, Q., & Yao, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.06 · Cited by 4
Impact of LKB1 status on radiation outcome in patients with stage III non-small-cell lung cancer
Sitthideatphaiboon, P., Nantavithya, C., Chantranuwat, P., Vinayanuwattikun, C., & Sriuranpong, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-55476-w · Cited by 3
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Lazzari, C., Verlicchi, A., Γκουντάκος, Α., Pilotto, S., Santarpía, M., CHAIB-OUKADOUR, I., Ramírez, J. L., Viteri, S., Morales-Espinosa, D., Dazzi, C., et al. (2016) · Pulmonary Therapy · doi:10.1007/s41030-016-0013-3 · Cited by 4

Authors: Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., & Jänne, P. A.
Affiliations: Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
1Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
ORCID: Calles, Antonio
Sholl, Lynette M.
Rodig, Scott J.
Hornick, Jason L.
Butaney, Mohit
Dahlberg, Suzanne E.
Oxnard, Geoffrey R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-06-14
Volume: 21
Issue: 12
Pages: 2851-2860
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-3112
OpenAlex: W2129277646
Cited by: 115
References: 50
Citations by year: 2026: 2 · 2025: 12 · 2024: 7 · 2023: 9 · 2022: 14 · 2021: 16 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 6 · 2016: 13 · 2015: 3
FWCI: 8.45
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: LKB1 loss, KRAS-mutant non-small cell lung cancer, lung adenocarcinoma, Peutz-Jeghers syndrome, smoking, metastasis, brain metastases, prognostic factors, tumor aggressiveness
MeSH terms: Adenocarcinoma of Lung, AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Genotype, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Risk Factors, Biomarkers, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Disease Progression, Cell Line, Tumor, Kaplan-Meier Estimate, Young Adult, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks